Akebia Therapeutics Inc. (NASDAQ: AKBA) is 14.52% higher on its value in year-to-date trading and has touched a low of $0.78 and a high of $2.48 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The AKBA stock was last observed hovering at around $1.31 in the last trading session, with the day’s gains setting it 0.11%.
Currently trading at $1.42, the stock is 39.52% and 27.48% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 3.78 million and changing 8.40% at the moment leaves the stock 11.93% off its SMA200. AKBA registered 33.96% gain for a year compared to 6-month loss of -8.39%.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The stock witnessed a 26.79% gain in the last 1 month and extending the period to 3 months gives it a 2.16%, and is 45.31% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 11.94% over the week and 9.08% over the month.
Akebia Therapeutics Inc. (AKBA) has around 167 employees, a market worth around $297.63M and $187.22M in sales. Profit margin for the company is -22.98%. Distance from 52-week low is 82.03% and -42.74% from its 52-week high. The company has generated returns on investments over the last 12 months (-67.22%).
The EPS is expected to grow by 7.02% this year.
Akebia Therapeutics Inc. (AKBA) Top Institutional Holders
The shares outstanding are 194.58M, and float is at 191.52M with Short Float at 6.85%.
Akebia Therapeutics Inc. (AKBA) Insider Activity
The most recent transaction is an insider sale by Dahan Michel,the company’sSVP, Chief Operating Officer. SEC filings show that Dahan Michel sold 34,840 shares of the company’s common stock on May 13 ’24 at a price of $1.26 per share for a total of $43898.0. Following the sale, the insider now owns 0.67 million shares.
Akebia Therapeutics Inc. disclosed in a document filed with the SEC on May 13 ’24 that Hadas Nicole R. (SVP, Chief Legal Officer) sold a total of 12,016 shares of the company’s common stock. The trade occurred on May 13 ’24 and was made at $1.26 per share for $15140.0. Following the transaction, the insider now directly holds 0.65 million shares of the AKBA stock.
Still, SEC filings show that on Feb 29 ’24, Butler John P. (CEO and President) disposed off 46,570 shares at an average price of $1.58 for $73581.0. The insider now directly holds 2,044,580 shares of Akebia Therapeutics Inc. (AKBA).
